한빛사논문
- 조회698
Soon-Jung Park1,2, Hyeok Kim3,4, Sunghun Lee5, Jongsoo Kim1,6, Taek-Hee Jung1,2, Seong Woo Choi7, Bong-Woo Park3,4, Sun-Woong Kang8, David A. Elliott9, Edouard G. Stanley9, Andrew G. Elefanty9, Kiwon Ban5,*, Hun-Jun Park3,4,10,*, Sung-Hwan Moon1,2,*
1Department of Medicine, Konkuk University School of Medicine, Seoul, Korea
2Research Institute, T&R Biofab Co. Ltd, Siheung, Korea
3Department of Medical Life Science, College of Medicine, The Catholic University of Korea, Seoul, Korea
4Division of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Korea
5Department of Biomedical Sciences, City University of Hong Kong, Kowloon, Hong Kong SAR
6Department of Surgery, Wexner Medical Center, Ohio State University, Columbus, Ohio, USA
7Department of Physiology, Department of BiomedicalSciences, College of Medicine, Seoul National University, Seoul, Korea
8Research Group for Biomimetic Advanced Technology, Korea Institute of Toxicology, Daejeon, Korea
9Monash Immunology and Stem Cell Laboratories, Monash University, Clayton, Victoria, Australia
10Cell Death Disease Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea
*Correspondence
Kiwon Ban, Department of Biomedical Sciences, City University of Hong Kong, 83 Tat Chee Ave, Kowloon,Hong Kong SAR.
Hun-Jun Park, Seoul St. Mary’s Hospital, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul,Korea.
Sung-Hwan Moon, Research Institute, T&R Biofab Co.Ltd, Siheung, Korea.
Soon-Jung Park, Hyeok Kim and Sunghun Leecontributed equally to this work.
Abstract
To the Editor:
Heart failure remains a leading cause of death worldwide. It exerts a severe social burden, particularly in a global ageing population. Despite the clinical significance of heart failure, currently available therapeutic strategies, including heart transplantation and left ventricular assist device, are not realistic owing to several limitations and drawbacks.1, 2 Therefore, in the past few decades, cell-based cardiac regeneration therapy has emerged as a promising alternative form of intervention.3 Among several potential cell candidates, cardiomyocytes derived from human pluripotent stem cells (hPSC-CMs) have been suggested as the next most promising cell type to treat heart diseases, as they are the most similar to primary human CMs. hPSC-CMs display a distinct cardiac phenotype featuring spontaneous contraction, coupling of cardiac excitation and contraction, and the expressions of cardiac-specific genes, ion channels and structural proteins. However, major issues, including the heterogeneity of hPSC-CMs, may cause tumourigenicity and arrhythmia may affect the long-term storage of hPSC-CMs, and cause poor survival, retention and engraftment of hPSC-CMs in vivo following implantation into diseased hearts. These issues must be resolved before pursuing clinical application.4 Here, we aimed to develop a comprehensive protocol in order to overcome the aforementioned obstacles.
논문정보
- Research article
- 2022년 01월 (BRIC 등록일 2022-02-07)
- 국내(교신)+국외 연구진
- 생명과학 > 세포생물학
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
관련분야 연구자보기
관련분야 논문보기
